Eribulin is primarily used in the treatment of metastatic breast cancer, particularly for patients who have previously undergone at least two chemotherapy regimens. It works by inhibiting the growth phase of microtubules, which are essential for cell division, thereby halting the proliferation of cancer cells. This mechanism makes it effective in slowing the progression of the disease and improving overall survival rates in certain cases. Additionally, Eribulin has shown promise in treating liposarcoma, a rare type of soft tissue sarcoma, offering a therapeutic option for patients with limited alternatives. Its application is carefully monitored due to potential side effects, such as neutropenia and peripheral neuropathy, which require regular patient assessment during treatment.